Related Experiment Video
Updated: Feb 15, 2026

Amplicon Sequencing using the Long-Read Sequencing Technologies
Published on: August 29, 2025
New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia
Sandy Elbitar1,2,3, Delia Susan-Resiga4, Youmna Ghaleb1,2,3
1INSERM LVTS U1148, hôpital Bichat-Claude Bernard, Paris, France.
Insights
Researchers identified new mutations in the APOB gene and the first compound heterozygote for APOB and PCSK9 mutations in families with autosomal dominant hypercholesterolemia (ADH). This advances ADH diagnosis and treatment.
Area of Science:
- Genetics
- Cardiovascular Disease
- Molecular Biology
Background:
- Autosomal dominant hypercholesterolemia (ADH) is a genetic disorder characterized by elevated LDL-C levels, significantly increasing the risk of coronary heart disease.
- Four genes (LDLR, APOB, PCSK9, APOE) are currently known to be implicated in ADH.
Purpose of the Study:
- To identify novel mutations in known ADH-associated genes or discover new genes involved in the condition.
- To investigate the genetic basis of ADH in thirteen French families.
Main Methods:
- Exome sequencing was performed on probands after excluding mutations in LDLR, PCSK9, APOE, and specific APOB exons.
- Segregation analysis and in-silico methods were used to assess the pathogenicity of identified mutations.
- Functional studies were conducted to elucidate the impact of a specific PCSK9 mutation.
Main Results:
- A novel p.Arg50Gln mutation in the APOB gene was identified in one family, located in a previously unassociated region.
- A patient with a severe ADH phenotype presented with both an APOB mutation (p.Ala3396Thr) and a PCSK9 mutation (p.Arg96Cys), representing the first reported compound heterozygote.
- Functional studies confirmed that the p.Arg96Cys PCSK9 mutation increases LDL receptor degradation.
Conclusions:
- Next-Generation Sequencing (NGS) is a powerful approach for identifying new mutations and compound heterozygotes in ADH.
- These findings contribute to a better understanding of ADH genetics, potentially improving diagnostic and therapeutic strategies.
Abstract:
Autosomal dominant hypercholesterolemia (ADH) is characterized by elevated LDL-C levels leading to coronary heart disease. Four genes are implicated in ADH: LDLR, APOB, PCSK9 and APOE. Our aim was to identify new mutations in known genes, or in new genes implicated in ADH. Thirteen French families with ADH were recruited and studied by exome sequencing after exclusion, in their probands, of mutations in the LDLR, PCSK9 and APOE genes and fragments of exons 26 and 29 of APOB gene. We identified in one family a p.Arg50Gln mutation in the APOB gene, which occurs in a region not usually associated with ADH. Segregation and in-silico analysis suggested that this mutation is disease causing in the family. We identified in another family with the p.Ala3396Thr mutation of APOB, one patient with a severe phenotype carrying also a mutation in PCSK9: p.Arg96Cys. This is the first compound heterozygote reported with a mutation in APOB and PCSK9. Functional studies proved that the p.Arg96Cys mutation leads to increased LDL receptor degradation. This work shows that Next-Generation Sequencing (exome, genome or targeted sequencing) are powerful tools to find new mutations and identify compound heterozygotes, which will lead to better diagnosis and treatment of ADH.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Incomplete Dominance
The Ratio of X Chromosome to Autosomes
Normal male Drosophila has a ratio of one X chromosome to two sets of autosomes. In contrast, normal female...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift

